BioTuesdays
Feature

Lipocine advancing pipeline, PDUFA for oral TRT

By Len Zehr With a PDUFA date of June 28 for an FDA decision on its oral testosterone replacement therapy (TRT) product candidate, TLANDO, Lipocine’s (NASDAQ:LPCN) next two pipeline product candidates are advancing...

May 31, 2016
Feature

In conversation with Paul Gunn

By Len Zehr As president and CEO of closely-held Soricimed Biopharma, Paul Gunn parlayed a 20-year career as a financial executive into funding the startup of Soricimed along with a tech transfer in 2005 facilitated by...

April 26, 2016
Feature

Xagenic readies X1 molecular diagnostic beta trials

Closely-held Xagenic plans to conduct beta studies this year, in advance of a major chlamydia and gonorrhea clinical trial, with its rapid X1 molecular diagnostic testing system in preparation for market launches in...

April 19, 2016
Feature

In conversation with Jerry Ropelato

By Len Zehr As CEO and founder of closely-held WhiteClouds, which operates the largest 3D color printing facility in the world, Jerry Ropelato is passionate about using the technology to create stunning models for the...

April 12, 2016
Feature

In conversation with David Luci

By Len Zehr As president, CEO and a co-founder of Dipexium Pharmaceuticals (NASDAQ:DPRX), David Luci, and executive chairman and co-founder, Robert DeLuccia, have spearheaded development of Locilex, which could be the...

March 8, 2016
Feature

In conversation with Charles Haff

By Len Zehr As a senior research analyst at Craig-Hallum Capital Group, Charles Haff covers medical devices and ancillary healthcare services. Previously, he covered medical devices at Dougherty & Company and was a...

February 16, 2016
Feature

In conversation with Amir Ronen

By Len Zehr As a founding member of closely-held Sensible Medical Innovations, Amir Ronen also has held the title of CEO since the company’s inception in late 2007. Mr. Ronen has over 15 years of experience in senior...

February 2, 2016
Feature

In conversation with Dr. Alan Schwebel

By Len Zehr As president and CEO of BioView (TASE:BIOV), Dr. Alan Schwebel has led the company, a world leader in automated fluorescence in situ hybridization (FISH) cell imaging and analysis, since 2009. Dr. Schwebel...

January 26, 2016
Feature

EyeGate developing non-invasive ophthalmic treatments

By Len Zehr EyeGate Pharmaceuticals (NASDAQ:EYEG) is developing a non-invasive drug delivery platform that uses an electrical process, known as iontophoresis, to deliver a corticosteroid to the front-and back-of-the-eye...

January 19, 2016
Feature

BioSight developing non-toxic drug against leukemia

By Len Zehr Closely-held BioSight is in clinical development with its lead chemotherapy drug, Astarabine, as a non-toxic treatment for hematologic malignancies, including acute myeloid leukemia (AML). “Treatment and...

January 5, 2016
Feature

Season’s Greetings (and JPM 2016)

Wow, what an interesting year 2015 has turned out to be! Everyone at BioTuesdays would like to wish you all a safe and happy holiday season. After taking a short break to spend time with family and friends, we will be...

December 22, 2015
Feature

In conversation with Kevin Smith

As the newly appointed chief commercial officer of closely-held Sensium Healthcare, a pioneer in wireless monitoring of patient vital signs, Kevin Smith is in charge of developing and executing the company’s global...

December 15, 2015
Feature

Oramed sees value creating events through 2016

By Len Zehr Oramed Pharmaceuticals’ (NASDAQ:ORMP) oral insulin development program has multiple value-creating events in the works through 2016. They include completion of an ongoing Phase 2b FDA multi-site study for...

December 1, 2015